Baillie Gifford & Co
SRPT icon

Baillie Gifford & Co’s Sarepta Therapeutics SRPT Stock Holding History

Baillie Gifford & Co’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-231
Closed -$31.8K – 421
2023
Q1 		$31.8K Buy
231
+32
+16% +$4.15K ﹤0.01% 308
2022
Q4 		$25.8K Hold
199
– – ﹤0.01% 323
2022
Q3 		$22K Hold
199
– – ﹤0.01% 323
2022
Q2 		$15K Buy
199
+22
+12% +$1.62K ﹤0.01% 370
2022
Q1 		$14K Hold
177
– – ﹤0.01% 412
2021
Q4 		$16K Hold
177
– – ﹤0.01% 406
2021
Q3 		$16K Sell
177
-28
-14% -$2.16K ﹤0.01% 396
2021
Q2 		$16K Hold
205
– – ﹤0.01% 379
2021
Q1 		$15K Buy
205
+27
+15% +$2.49K ﹤0.01% 365
2020
Q4 		$30K Buy
+178
New +$26.4K ﹤0.01% 293

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co's SRPT Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 231 shares — an estimated $31.8K sold.

Baillie Gifford & Co first reported a position in SRPT in Q4 2020 and held it in 10 quarters. The position peaked at $31.8K in Q1 2023. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 231 Sarepta Therapeutics shares in Q2 2023, an estimated $31.8K.
  • Baillie Gifford & Co first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 10 quarters.
  • Baillie Gifford & Co's Sarepta Therapeutics position peaked at $31.8K in Q1 2023.
  • 404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.